文献速递头痛与眩晕

曲坦类药物治疗偏头痛的性别差异:系统综述与荟萃分析

Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis.
PubMed 文献 · Neurology · 2020-11-18

该系统综述与荟萃分析检索了截至2019年12月12日的多项数据库,最终纳入19篇报告性别特异性结果的文献,涵盖2280名男性和13899名女性。分析显示,男女在2小时头痛缓解和无痛率上无差异,但男性头痛复发风险(RR 0.64,95%CI 0.55-0.76)和不良事件风险(RR 0.82,95%CI 0.72-0.93)均低于女性;男性曲坦类药物暴露量较低(AUC的RoM 0.69,95%CI 0.60-0.81;峰浓度的RoM 0.72,95%CI 0.64-0.82)。

要点

  • 男女偏头痛患者对曲坦类药物的2小时疗效无显著差异。
  • 男性头痛复发风险(RR 0.64)和不良事件风险(RR 0.82)低于女性。
  • 女性曲坦暴露量较高,但未转化为更高的应答率。

核心结论

  • 曲坦类药物治疗偏头痛的性别差异研究数量有限,现有证据显示男性不良事件和头痛复发风险较低,可能与药物暴露差异有关。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、MEDLINE、Cochrane Library、Embase和Web of Science至2019年12月12日,纳入19篇报告性别特异性结果的文献,共2280名男性和13899名女性。

主要发现

  • 2小时头痛缓解和无痛率无性别差异。
  • 男性头痛复发风险低于女性(男性与女性RR 0.64,95%CI 0.55-0.76)。
  • 男性不良事件风险低于女性(RR 0.82,95%CI 0.72-0.93)。
  • 男性AUC低于女性(RoM 0.69,95%CI 0.60-0.81)。
  • 男性峰浓度低于女性(RoM 0.72,95%CI 0.64-0.82)。

临床怎么用

  • 临床处方曲坦类药物时需关注女性患者不良事件和头痛复发风险可能更高。
  • 女性曲坦暴露量较高但疗效未增强,提示剂量调整需结合个体反应。

局限性

  • 仅19篇文献报告性别特异性结果,相关研究数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effect of sex on clinical response to triptans in migraine and to determine whether these differences are related to pharmacokinetics of triptans in men and women, we performed a systematic review and meta-analysis. METHODS: We searched clinical trials distinguishing clinical response to or pharmacokinetic parameters of triptans between sexes in PubMed, MEDLINE, Cochrane Library, Embase, and Web of Science up to Dec 12, 2019. Analysis was based on data extracted from published reports. Male-to-female pooled risk ratios (RR) were calculated for clinical outcomes and pooled ratio of means (RoM) for pharmacokinetic outcomes using random-effects models. RESULTS: Of 1,188 publications on clinical trials with triptans, 244 were identified with sex-related search terms. Only 19 publications presented sex-specific results, comprising n = 2,280 men and n = 13,899 women. No sex differences were revealed for 2-hour headache and pain-free responses, but men had a lower risk for headache recurrence (male-to-female RR 0.64, 95% confidence interval [CI]: 0.55-0.76, Q = 0.81) and adverse events (RR 0.82, 95% CI: 0.72-0.93, Q = 4.93). Men had lower drug exposure with lower area under the curve (RoM 0.69, 95% CI: 0.60-0.81, Q = 18.06) and peak drug concentration (RoM 0.72, 95% CI: 0.64-0.82, Q = 8.24) than women. CONCLUSIONS: Remarkably few publications about sex differences in triptan response are available. The limited number of eligible studies show sex differences in adverse event frequency, which may be partly because of drug exposure differences. This higher drug exposure in women is not reflected in different response rates. Despite higher exposure, women have higher headache recurrence rates possibly because of longer attack duration related to sex hormonal changes.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. van Casteren DS, Kurth T, Danser AHJ, et al. Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis. Neurology. 2020. PMID: 33208542. doi:10.1212/WNL.0000000000011216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。